Omega Therapeutics, Inc.
OMGA · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $67,290 | $124,089 | $176,482 | $165,981 |
| - Cash | $30,377 | $45,852 | $60,033 | $68,443 |
| + Debt | $128,133 | $126,949 | $127,615 | $128,428 |
| Enterprise Value | $165,046 | $205,186 | $244,064 | $225,966 |
| Revenue | $2,612 | $2,134 | $2,360 | $989 |
| % Growth | 22.4% | -9.6% | 138.6% | – |
| Gross Profit | $2,612 | -$7,206 | $544 | -$792 |
| % Margin | 100% | -337.7% | 23.1% | -80.1% |
| EBITDA | -$16,420 | -$15,967 | -$18,635 | -$18,918 |
| % Margin | -628.6% | -748.2% | -789.6% | -1,912.8% |
| Net Income | -$16,444 | -$16,305 | -$20,129 | -$20,214 |
| % Margin | -629.6% | -764.1% | -852.9% | -2,043.9% |
| EPS Diluted | -0.3 | -0.3 | -0.36 | -0.37 |
| % Growth | 0% | 16.7% | 2.7% | – |
| Operating Cash Flow | -$14,015 | -$12,672 | -$11,805 | -$17,090 |
| Capital Expenditures | -$16 | -$396 | -$535 | -$1,111 |
| Free Cash Flow | -$14,031 | -$13,068 | -$12,340 | -$18,201 |